Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK5 | P34947 | 4/20 | 0.51 |
| ▸ | PAK4 | O96013 | 8/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5366152 | 0.85 | GSK3B (0.51) | PAK4JAK3PDGFRBKDRGSK3B | |
| SCHEMBL5364206 | 0.83 | JAK3 (0.47) | PAK4ALDH1A1JAK3KDRMEN1 | |
| SCHEMBL5368286 | 0.82 | PAK4 (0.69) | GRK5PAK4JAK3PDGFRBKDR | |
| SCHEMBL5370079 | 0.82 | PAK4 (0.51) | GRK5PAK4ALDH1A1PDGFRBKDR | |
| SCHEMBL5366782 | 0.80 | PDPK1 (0.60) | ALDH1A1JAK3KDRMEN1KMT2A | |
| SCHEMBL25313935 | 0.80 | GRK5 (0.63) | GRK5PDGFRBKDREGFRFGFR1 | |
| SCHEMBL25313929 | 0.80 | GRK5 (0.63) | GRK5PDGFRBKDREGFRFGFR1 | |
| SCHEMBL5368518 | 0.79 | PAK4 (0.75) | PAK4JAK3 | |
| SCHEMBL5362148 | 0.78 | KDR (0.48) | ALDH1A1JAK3PDGFRBKDRGSK3B | |
| SCHEMBL6666023 | 0.77 | ALDH1A1 (0.51) | GRK5PAK4ALDH1A1JAK3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
| EP-1247803-A2 | Indolinone compounds suitable for modulation of protein kinases | Sugen, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | GRK5 205/4885PAK4 682/4885ALDH1A1 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.